Published in Immunology on March 01, 2007
Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169. PLoS One (2012) 1.04
Targeting antigens to dendritic cell receptors for vaccine development. J Drug Deliv (2013) 0.94
Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody. PLoS One (2011) 0.80
DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J (2005) 2.03
Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci U S A (1994) 1.98
Polycation gene delivery systems: escape from endosomes to cytosol. J Pharm Pharmacol (2003) 1.92
Transferrin-polycation-mediated introduction of DNA into human leukemic cells: stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels. Proc Natl Acad Sci U S A (1990) 1.79
Receptor-mediated endocytosis of transferrin-polycation conjugates: an efficient way to introduce DNA into hematopoietic cells. Proc Natl Acad Sci U S A (1990) 1.64
A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol (1997) 1.61
Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J Immunother (2001) 1.52
Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum. Immunity (1999) 1.45
Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest (1997) 1.40
Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res (2006) 1.33
Role of the mannose receptor in the immune response. Curr Mol Med (2001) 1.28
Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J Biol Chem (1998) 1.21
Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci U S A (1995) 1.16
Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol (1998) 1.13
Thermodynamics of cationic lipid binding to DNA and DNA condensation: roles of electrostatics and hydrophobicity. J Am Chem Soc (2002) 1.12
Biological properties of poly-L-lysine-DNA complexes generated by cooperative binding of the polycation. J Biol Chem (2001) 1.12
Microparticles and nanoparticles as delivery systems for DNA vaccines. Crit Rev Ther Drug Carrier Syst (2003) 1.12
Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. J Biol Chem (1999) 1.11
Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine (1996) 1.11
MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother (2000) 1.10
Galactose-PEI-DNA complexes for targeted gene delivery: degree of substitution affects complex size and transfection efficiency. J Control Release (2003) 1.07
A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci U S A (2003) 1.07
Biochemical and functional characterization of DNA complexes capable of targeting genes to hepatocytes via the asialoglycoprotein receptor. J Biol Chem (1997) 1.05
Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology (2006) 1.03
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res (2006) 1.03
Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun (2002) 1.02
Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur J Immunol (2000) 1.01
Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine (2000) 1.01
In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate. FASEB J (2000) 0.99
Muramyl dipeptide bound to poly-L-lysine substituted with mannose and gluconoyl residues as macrophage activators. Glycoconj J (1989) 0.95
Efficient gene delivery into human dendritic cells by adenovirus polyethylenimine and mannose polyethylenimine transfection. Hum Gene Ther (1999) 0.94
Gene transfer by DNA/glycosylated polylysine complexes into human blood monocyte-derived macrophages. Hum Gene Ther (1996) 0.92
Receptor-mediated gene transfer into macrophages. Proc Natl Acad Sci U S A (1996) 0.92
Targeting of Synthetic Gene Delivery Systems. J Biomed Biotechnol (2003) 0.90
Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin Cancer Res (2000) 0.89
CTL in mice immunized with human mucin 1 are MHC-restricted. J Immunol (1995) 0.88
Synthesis of a non-viral vector for gene transfer via the high-affinity neurotensin receptor. Brain Res Brain Res Protoc (2000) 0.85
Delivery of a heterologous antigen by a registered Salmonella vaccine (STM1). FEMS Microbiol Lett (2003) 0.84
Cationic transfection lipids in gene therapy: successes, set-backs, challenges and promises. Curr Med Chem (2003) 0.82
Breast cancer immunotherapy: current status and future prospects. Immunol Cell Biol (1996) 0.82
Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochem Biophys Res Commun (2004) 0.81
Transfer of the human Alpha1-antitrypsin gene into pulmonary macrophages in vivo. Am J Respir Cell Mol Biol (1998) 0.81
Nonviral gene delivery: thinking of silica. Gene Ther (2006) 0.81
Applications of peptide mimetics in cancer. Curr Med Chem (2002) 0.79
New cationized LDL-DNA complexes: their targeted delivery to fibroblasts in culture. Drug Deliv (2003) 0.78
Preparation and characterisation of liposomes containing mannosylated phospholipids capable of targetting drugs to macrophages. Biochim Biophys Acta (1986) 0.78
Synthesis, characterisation and in vivo behaviour of a norfloxacin-poly(L-lysine citramide imide) conjugate bearing mannosyl residues. J Drug Target (2000) 0.77
A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med (2004) 2.93
Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol (2004) 2.33
Pathogen recognition and development of particulate vaccines: does size matter? Methods (2006) 2.09
Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine (2002) 1.97
IMGT/HighV QUEST paradigm for T cell receptor IMGT clonotype diversity and next generation repertoire immunoprofiling. Nat Commun (2013) 1.71
Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One (2012) 1.64
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov (2012) 1.62
Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg (2012) 1.62
Natural regulatory T cells and persistent viral infection. J Virol (2007) 1.62
Carbohydrate residues downstream of the terminal Galalpha(1,3)Gal epitope modulate the specificity of xenoreactive antibodies. Immunol Cell Biol (2007) 1.59
Characterization of mice lacking the tetraspanin superfamily member CD151. Mol Cell Biol (2004) 1.57
Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A (2013) 1.57
Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. PLoS Pathog (2011) 1.51
Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog (2009) 1.46
Honorary Membership of International Xenotransplantation Association conferred upon Professor Ian F C McKenzie (September 18, 2007). Xenotransplantation (2009) 1.41
Pim-1 associates with protein complexes necessary for mitosis. Chromosoma (2002) 1.39
Investigation of a novel approach to scoring Giemsa-stained malaria-infected thin blood films. Malar J (2008) 1.35
Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm (2007) 1.34
Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res (2006) 1.33
Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses. J Infect Dis (2008) 1.28
A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use. J Immunol (2009) 1.28
Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS One (2008) 1.25
Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res (2005) 1.24
Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. Am J Trop Med Hyg (2003) 1.22
A regulatory role for CD37 in T cell proliferation. J Immunol (2004) 1.20
Enhanced immunogenicity of heat shock protein 70 peptide complexes from dendritic cell-tumor fusion cells. J Immunol (2006) 1.16
Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. Vaccine (2006) 1.16
Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons. Xenotransplantation (2004) 1.15
Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta. PLoS Pathog (2009) 1.14
Heroes or villains? T regulatory cells in malaria infection. Trends Parasitol (2009) 1.12
Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods (2006) 1.11
Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur J Immunol (2008) 1.10
Experimentally induced blood stage malaria infection as a tool for clinical research. Trends Parasitol (2012) 1.09
Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol (2004) 1.09
Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection. PLoS Pathog (2009) 1.08
A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci U S A (2003) 1.07
Defining target antigens for CD25+ FOXP3 + IFN-gamma- regulatory T cells in chronic hepatitis C virus infection. Immunol Cell Biol (2007) 1.06
Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC. Eur J Immunol (2009) 1.05
NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J Infect Dis (2012) 1.04
Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients. Crit Care (2014) 1.04
Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology (2006) 1.03
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res (2006) 1.03
Dendritic cells induce immunity and long-lasting protection against blood-stage malaria despite an in vitro parasite-induced maturation defect. Infect Immun (2004) 1.02
Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer. Angew Chem Int Ed Engl (2011) 1.02
Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun (2002) 1.02
Round and round we go: cyclic peptides in disease. Curr Med Chem (2006) 1.01
Cripto: a novel target for antibody-based cancer immunotherapy. Cancer Res (2004) 1.01
Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. Am J Trop Med Hyg (2006) 1.00
Hot, sweet and sticky: the glycobiology of Plasmodium falciparum. Trends Parasitol (2008) 0.99
Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines (2008) 0.98
The effector T cell response to ryegrass pollen is counterregulated by simultaneous induction of regulatory T cells. J Immunol (2010) 0.98
Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design. J Mol Biol (2002) 0.96
Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum. Malar J (2014) 0.95
The activin A antagonist follistatin inhibits asthmatic airway remodelling. Thorax (2012) 0.94
Apoptosis and dysfunction of blood dendritic cells in patients with falciparum and vivax malaria. J Exp Med (2013) 0.94
Crystal structure of a non-canonical high affinity peptide complexed with MHC class I: a novel use of alternative anchors. J Mol Biol (2002) 0.94
Direct processing and presentation of antigen from malaria sporozoites by professional antigen-presenting cells in the induction of CD8 T-cell responses. Immunol Cell Biol (2005) 0.93
Reactive oxygen species level defines two functionally distinctive stages of inflammatory dendritic cell development from mouse bone marrow. J Immunol (2010) 0.93
Cell-penetrating peptides: application in vaccine delivery. Biochim Biophys Acta (2009) 0.92
Antibodies to a single, conserved epitope in Anopheles APN1 inhibit universal transmission of Plasmodium falciparum and Plasmodium vivax malaria. Infect Immun (2013) 0.92
Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection. Infect Immun (2009) 0.91
Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations. J Clin Invest (2002) 0.91
The adjuvanticity of a mannosylated antigen reveals TLR4 functionality essential for subset specialization and functional maturation of mouse dendritic cells. J Immunol (2008) 0.91
The challenge of assessing infant vaccine responses in resource-poor settings. Expert Rev Vaccines (2010) 0.90
Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev Vaccines (2008) 0.90
Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. J Med Chem (2005) 0.90
Antagonistic effects of human cyclic MBP(87-99) altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation. J Med Chem (2002) 0.90